8. Tougeron D et al. Efficacy of Adjuvant Chemotherapy in Colon Cancer With Microsatellite Instability: A Large Multicenter AGEO Study. J Natl Cancer Inst. 2016;108(7) 9. Goldstein J et al. Multicenter retrospective analysis of metastatic col...
Microsatellite instability-high colorectal cancerimmune checkpoint inhibitorpembrolizumabprogrammed death-ligand 1tumor mutational burdenIntroduction Microsatellite instability-high (MSI-H) colorectal cancer (CRC) represents a unique subset of CRC characterized by elevated neoantigen expression and a high degree ...
2017年5月,美国食品药品监督管理局(FDA)加速批准了默沙东的帕博利珠单抗Pembrolizumab(KEYTRUDA,即常说的K药)治疗带有错配修复缺陷(deficient mismatch repair,dMMR)或高度微卫星不稳定性(microsatellite instability,MSI)的实体瘤患者,成为首个“不看部位看marker”的广谱抗肿瘤免疫药物(异癌同治),这在肿瘤精准药物治疗上...
Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study[J]. Lancet Oncol, 2022...
8. Tougeron D et al. Efficacy of Adjuvant Chemotherapy in Colon Cancer With Microsatellite Instability: A Large Multicenter AGEO Study. J Natl Cancer Inst. 2016;108(7) 9. Goldstein J et al. Multicenter retrospective analysis of metastatic colorectal cancer (CRC) with high-level microsatellite ins...
8. Tougeron D et al. Efficacy of Adjuvant Chemotherapy in Colon Cancer With Microsatellite Instability: A Large Multicenter AGEO Study. J Natl Cancer Inst. 2016;108(7) 9. Goldstein J et al. Multicenter retrospective analysis of metastatic colorectal cancer (CRC) with high-level microsatellite ins...
基于此,美国食品药品监督管理局(FDA)于2017 年批准抗PD-1抗体帕博利珠单抗(pembrolizumab)用于先前治疗后进展、无满意替代治疗方案的dMMR/MSI-H晚期/转移性实体瘤患者。另一抗PD-1抗体纳武利尤单抗( nivolumab)也分别于2017 年和2018 年获批单药及联合低剂量抗细胞毒性T 淋巴细胞相关抗原(CTLA-4)抗体伊匹木单抗(ip...
3.Aurelien Marabelle, et al., Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/ Mismatch Repair–Deficient Cancer: Results From the Phase II KEYNOTE-158 Study, J Clin Oncol 38:1-10. 4.Dung T. Le, et al., Phase II Open-Label Study of Pembrolizumab in...
European Commission Approves KEYTRUDA® (pembrolizumab) as First-Line Treatment in Adult Patients With Metastatic Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Colorectal Cancer Save Ja...
Thierry Andre, MD, discusses the results of the KEYNOTE-177 trial in metastatic colorectal cancer. Thierry Andre, MD Pembrolizumab (Keytruda) monotherapy has become the new frontline standard of care for patients with microsatellite instability–high (MSI-H)/mismatch repair deficient (dMMR) ...